Top Hill Staffer Says CMS Breakthrough Coverage Pulled Due to Cost
This article was originally published in The Gray Sheet
A House Energy and Commerce staffer said the committee dropped a Medicare reimbursement provision for breakthrough devices from their Cures draft bill because of cost but lawmakers haven't given up on the issue yet.
You may also be interested in...
Device tax, reimbursement predictability and empowering women in the medtech industry are some of Martha Shadan's top priorities for her two-year term as board chair of AdvaMed Accel, the small-company-advocacy arm of the trade group.
The US Centers for Medicare and Medicaid Services has withdrawn efforts on a proposed rule to offer faster Medicare reimbursement to novel devices, but the agency still plans to work on different approaches to provide "timely patient access" to device innovations, a spokeswoman said. AdvaMed says it is disappointed by CMS's decision to withdraw the rule after a 10-month review by the Office of Management and Budget.
Following House passage of a combined House/Senate 21st Century Cures package Nov. 30, the Senate will take up the bill on Dec. 5 or 6, said Senate HELP Committee Chair Lamar Alexander, R-Tenn., who shepherded a similar package of medical innovation bills through the committee earlier this year. While some Democrats remain vocal in opposing the bill based on worries that it will water-down FDA safety protections and funding concerns, the House vote showed lopsided support, and the Senate is expected to pass it and the president to sign.